Development of a simple HPLC-UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma by Nannetti, Giulio et al.
 1 
Short communication  
 
Development of a simple HPLC-UV method for the determination of the 
hepatitis C virus inhibitor simeprevir in human plasma 
 
 
 
Giulio Nannettia, Silvana Pagnia,b, Saverio G. Parisia,b, Alfredo Albertia,  
Arianna Loregiana,b,1*, Giorgio Palùa,b,1 
 
 
aDepartment of Molecular Medicine, University of Padua, Padua, Italy 
bClinical Microbiology and Virology Unit, Padua University Hospital, Padua, Italy 
 
1These authors contributed equally to this work. 
 
*Corresponding author at: Department of Molecular Medicine, University of Padua, Via Gabelli 63, 
35121 Padua, Italy. Tel.: +39 049 8272363; fax: +39 049 8272355; E-mail address: 
arianna.loregian@unipd.it (A. Loregian).  
 
Abstract 
A simple high-performance liquid chromatography method for the determination of the hepatitis C 
virus protease inhibitor simeprevir in human plasma was developed and validated.  The method 
involved a rapid and simple solid-phase extraction of simeprevir using Oasis HLB 1cc cartridges, 
an isocratic reversed-phase liquid chromatography on an XTerra RP18 (150 mm × 4.6 mm, 3.5 
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m) column, and ultraviolet detection at 225 nm.  The mobile phase consisted of phosphate buffer 
(pH 6, 52.5 mM) and acetonitrile (30:70, v/v).  This assay proved to be sensitive (lower limit of 
quantification of 0.05 g/ml), linear (correlation coefficients  0.99), specific (no interference with 
various potentially co-administrated drugs), reproducible (both intra-day and inter-day coefficients 
of variation  8.3%), and accurate (deviations ranged from – 8.0 to 1.2% and from –3.3 to 6.0% 
for intra-day and inter-day analysis, respectively).  The method was applied to therapeutic 
monitoring of patients undergoing simeprevir treatment for hepatitis C and proved to be robust and 
reliable.  Thus, this method provides a simple, sensitive, precise and reproducible assay for dosing 
simeprevir that can be readily adaptable to routine use by clinical laboratories with standard 
equipment.   
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1.  Introduction 
Simeprevir (SMV, also known as TMC435) is a novel inhibitor approved for the treatment 
of chronic hepatitis C virus (HCV) infection [1].  HCV infection affects more than 150 million 
people worldwide and represents the leading cause of liver failure and hepatocellular carcinoma 
[2].   
For many years, the combination therapy with ribavirin and pegylated interferon α has been 
the standard of care, achieving a sustained virological response (SVR) in 80 % of patients with 
HCV genotypes 2 and 3 but in only 50 % of subjects with HCV genotype 1, and often causing 
significant side effects [3, 4].  
Major advances in the treatment of HCV infection have recently been obtained with the 
development of direct-acting antivirals (DAAs) that target viral nonstructural proteins.  SMV is a 
once-daily oral HCV N3S/4A protease inhibitor for the treatment of chronic HCV genotype 1 
infection as a component of combination antiviral therapy [5].  SMV has demonstrated high SVR 
rates in patients with HCV genotype 1 infection during phase II and III trials [5].  
SMV is metabolized by the cytochrome P450 (CYP) system, primarily CYP3A, and is a 
substrate and/or an inhibitor of several drug transporters.  Thus, it is prone to metabolic drug–drug 
interactions with drugs that are CYP3A inhibitors or inducers; in fact, coadministration of these 
drugs may increase or decrease plasma concentrations of SMV, respectively [6].  In addition, SMV 
is a mild inhibitor of CYP1A2, thus potentially affecting drugs that are mainly metabolized by this 
enzyme.  Two populations at particularly high risk of drug-drug interactions due to complex, long-
term therapeutic regimens are transplant recipients receiving immunosuppressants and HCV-HIV 
coinfected patients receiving antiretroviral therapy [7].  Because coadministration of SMV with 
these medications has the potential to significantly alter the drug exposure, a user-friendly method 
sufficiently sensitive and robust to measure plasma levels of SMV in different therapeutic 
regimens is needed, in order to maximize the efficacy of treatment and avoid drug-related toxicity. 
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To the best of our knowledge, only one method for quantifying SMV in plasma, which 
employs liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS), has been 
published so far [8].  However, since MS/MS facilities are not always available in standard 
hospital laboratories, analytical methods employing UV detection need to be developed.  
In this report, we describe the development and validation of the first HPLC-UV method 
for the determination of SMV in plasma of HCV-infected patients.  The proposed technique uses a 
simple solid-phase extraction (SPE) procedure, an isocratic elution on a reversed-phase column, 
and UV detection.  The method is sufficiently robust and sensitive to measure therapeutically 
relevant levels of SMV, employs standard equipment and is easy to set up, and thus its use is 
feasible in most hospital laboratories.  In addition, we evaluated the stability of SMV to heat 
treatment that is recommended to inactivate HCV and/or HIV particles in biological samples and 
also to cover several common conditions to which samples can be subjected in the clinical setting. 
 
2.  Material and methods 
2.1  Chemicals and reagents 
SMV was obtained from Alsachim (Illkirch, France).  Acetonitrile for HPLC (Gradient Grade, 
LiChrosolv) was from Merck (Darmstadt, Germany), methanol for chromatography was from 
Carlo Erba (Milan, Italy).  All other chemicals were of analytical grade and purchased from J. T. 
Baker (Deventer, The Netherlands).  Ultrapure water was purified by a Milli-Q apparatus 
(Millipore, Bedford, MA, USA).  Control human plasma (with K3EDTA as anticoagulant) was 
purchased from Roche (Milan, Italy; TaqScreen West Nile Virus COBAS kit). 
 
2.2  Equipment and chromatographic conditions 
The chromatographic system consisted of an Alliance 2695 Separation Module equipped with an 
online degasser and an automatic injector thermostated at 20°C, and a 2996 Photodiode Array 
Detector coupled with the Empower data acquisition software (version 2.0) (Waters, Milford, MA, 
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USA).  Separations were performed on an XTerra RP18 (150 mm × 4.6 mm, particle size 3.5 μm; 
Waters) analytical column equipped with an XTerra RP18 (20 mm × 3.9 mm, particle size 5 μm; 
Waters) guard column. Both columns were maintained at 40°C.  The isocratic mobile phase 
consisted of a mixture of acetonitrile-sodium phosphate buffer (pH 6.0, 52.5 mM) (70:30, v/v) and 
was filtered through a 0.2 μm nylon filter membrane (Millipore, Bedford, MA, USA) before use.  
The flow rate was 1.0 ml/min, and the assay runtime was 30 min.  Absorbance was measured at 
225 nm.  An Extraction Manifold (Waters) liquid handling system was used to perform the sample 
preparation.  A DRI-BLOCK DB-3 evaporator (Techne, Stone, United Kingdom) was used for 
drying the solid phase extraction (SPE) eluates. 
 
2.3  Preparation of stock solutions, working solutions, calibration standards and quality control 
(QC) samples 
A stock solution of 1 mg/ml SMV was prepared in 100% dimethyl sulfoxide (DMSO).  The stock 
solution was diluted further with DMSO to obtain working solutions with concentrations of 500, 
250, 100, 50, 25, 12.5, 5 and 2.5 g/ml.  The stock and working solutions were stored at –20°C.  
Plasma calibration standards at 20, 10, 5, 2, 1, 0.5, 0.2, 0.1 and 0.05 g/ml were prepared by 1:50 
dilution of the respective working solution in control human plasma.  Of note, the total added 
volume of organic solvent in all samples corresponded to 2% of biological sample in accordance to 
FDA guidelines [9] recommending that non-biological matrix (i.e., organic solvent) should 
correspond to only  2% of the volume of final biological samples.  QC samples at the lower limit 
of quantification (LLOQ = 0.05 g/ml), low (0.2 g/ml), medium (1 g/ml), high (5 g/ml) and 
the upper limit of quantification (ULOQ = 20 g/ml) concentration levels were prepared by 
diluting the working solutions in plasma.  The QC samples were prepared in batches at the same 
occasion, stored at –20°C, and then thawed and thermized at 60°C for 60 min on the day of 
analysis.  Because of potential degradation of SMV when exposed to daylight [8], all solutions and 
samples containing SMV were protected from daylight during preparation, storage, and analysis.  
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2.4  Sample pretreatment and preparation  
Blood samples of patients (5 ml) were collected in tubes with K3EDTA as anticoagulant and 
transported to the laboratory on ice.  Plasma was immediately isolated by centrifugation at 3,000 
rpm for 10 min at 4°C (Sigma Centrifuge, Model 2K15) and stored at –80°C until analysis.  On the 
day of analysis, plasma samples were thawed and heated at 60°C for 60 min.  The analysis of 
stability of SMV under these conditions is reported in the Section 3.3.  Sample clean-up was 
achieved by a solid-phase extraction (SPE) procedure as follows.  Aliquotes (0.5 ml) of heat-
inactivated plasma samples were mixed with an equal volume of acetonitrile, vortexed for 1 min, 
and then centrifuged at 13,000 rpm for 5 min.  Supernatants were transferred in clean tubes and 
diluted 1:1 with 5% NH4OH.  The samples were then loaded onto Oasis HLB 1cc cartridges 
(Waters, Milford, MA, USA).  The cartridges were successively washed with 1 ml of 70% 
methanol (v/v).  The analytes were eluted with 1 ml of methanol.  The eluates were evaporated to 
dryness under a stream of nitrogen at 40°C.  The dried extracts were reconstituted with 125 l of 
mobile phase.  The reconstituted samples were centrifuged at 13,000 rpm for 5 min at room 
temperature and 20 l of the supernatant were injected onto the HPLC system.  Blood samples 
were protected from daylight during sampling, storage and shipment, and sample preparation was 
performed under yellow light conditions. 
 
2.5  Recovery 
The overall recovery of SMV from human plasma was determined at the LLOQ, low-, medium-, 
high-QC, and ULOQ level by comparing the peak area response of extracted plasma samples (four 
samples for each concentration level) with that obtained by direct injection of the same amount of 
drug diluted in mobile phase (four samples for each concentration level).  The extraction recovery 
was calculated using the ratio of the response and the concentration factor of the assay (500:125) 
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and was expressed as a percentage of the response of the calculated amount of SMV diluted in 
mobile phase and directly injected onto the HPLC, which corresponds to 100% recovery.  
 
2.6  Analytical method validation 
The validation of the assay was based on the FDA guidelines for Bioanalytical Method Validation 
[9].  Assay validation involved linearity, specificity, accuracy, precision, limit of detection (LOD), 
and lower limit of quantification (LLOQ) determination.  Intra-day and inter-day precision values 
were estimated by assaying plasma samples spiked with five different concentrations of SMV five 
times on the same day and on four separate days to obtain the coefficient of variation (CV).  
Accuracy was determined as the percentage of deviation between nominal and measured 
concentration (% bias).  Analytic interferences from endogenous substances were investigated by 
testing ten different lots of blank human plasma.  The method specificity was also investigated by 
analyzing both plasma spiked with potentially co-administered drugs and patient samples.   
 
2.7.  Stability studies 
Since photochemical degradation of SMV in plasma under daylight conditions was previously 
reported [8], all stability experiments were performed under yellow light conditions.  The stability 
of SMV in plasma under the thermization process (60°C for 60 min) was assessed as follows: four 
series of calibration samples at the nine concentrations reported above (0.05–20.0 g/ml) and of 
samples at the LLOQ, low-, medium-, high-QC, and ULOQ level were prepared.  Two series were 
heated at 60°C for 60 min, while the thermization procedure was omitted in the other two.  The 
four series were then subjected simultaneously to SPE and analyzed.  The slope of the calibrations 
curves was compared as well as the SMV levels in QC samples.  Further studies of the stability of 
SMV in plasma included: (a) after three freeze-thaw cycles; (b) storage at room temperature (RT) 
for 96 h; and (c) storage at –80°C for 3 months.  For each tested condition, six series of LLOQ, 
low-, medium-, high-QC, and ULOQ plasma samples were prepared.  Three series were 
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immediately analyzed, while the three remaining series were subjected to the storage or treatment 
conditions under examination.  The SMV levels in samples were compared.  Additionally, the 
stabilities of dried extracts and of extracts reconstituted in mobile phase were analyzed: dried 
extracts (i.e., after SPE) containing SMV at LLOQ, low-, medium-, high-QC, and ULOQ 
concentration were analyzed in triplicate either immediately after preparation, or after being stored 
at –20°C for 120 h.  Processed samples (i.e., reconstituted in mobile phase) were analyzed in 
triplicate immediately after preparation and after being left for 96 h in the autosampler 
thermostated at 20°C.  The results were compared. 
 
3.  Results and discussion  
3.1  Method development 
To establish an efficient method for SMV extraction from plasma, several purification methods 
were compared.  Initially, a liquid–liquid extraction method employing acetonitrile was attempted 
for sample preparation, which was based on a previously published study [8].  However, the 
chromatography resulting from this method showed significant interference between background 
plasma peaks and the SMV peak (data not shown).  Liquid-liquid extraction methods with 
different solvents (i.e., methanol, ethylacetate, ether, chloroform, dichloroethane, and 
dichloromethane) were then tested, but they gave in general low recovery and/or low clean-up 
efficiency (data not shown).  Therefore, solid phase extraction (SPE) was attempted.  Among the 
SPE cartridges that we tested (Oasis HLB, Oasis MAX, Oasis WAX, and Oasis MCX cartridges 
from Waters; Bond-Elut phenyl boronic acid, Bond-Elut C18 cartridges from Varian; Si-Sax 
cartridges from Agilent), the Waters Oasis HLB cartridges proved to be the most adequate in terms 
of extraction efficiency and reliability.  However, when SPE was performed with the standard 
procedure recommended by the producer, a very low recovery (around 20-30%) was observed.  No 
significant increase in recovery was obtained by using the 3cc or 6 cc cartridges instead of the 1cc 
cartridges.  Thus, we worked to improve the SPE procedure by introducing several modifications.  
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First, since SMV is known to be extensively bound to plasma proteins (> 99.9%) [5], that could 
explain the low recovery, the SPE was preceded by a protein precipitation step with acetonitrile 
and subsequent basification by diluting the sample 1:1 with 5% NH4OH (while no improvement 
was observed by acidifying the sample with 4% H3PO4).  Second, the condition and equilibration 
steps of the Oasis HLB cartridges were omitted, since they were found to affect the final recovery; 
in addition, the elimination of these steps allowed shortening and simplifying the overall extraction 
procedure.  Third, a washing step with 70% methanol instead of the 5% concentration suggested 
by the producer, greatly improved the sample clean-up giving a cleaner baseline at the retention 
time of SMV without decreasing the drug recovery.  Fourth, elution with 1 ml of methanol was 
found to be crucial since lower elution volumes significantly decreased SMV recovery; elution 
with acidified methanol did not further increase the final recovery.  All these modifications, when 
combined, allowed to obtain a good sample clean-up along with a high and constant recovery of 
SMV (see Fig. 1 and Section 3.2). 
Different HPLC columns were tested for their ability to separate SMV from background 
peaks.  The columns that were tested included a Waters Atlantis dC18 (150 mm × 3.9 mm, 5 m) 
column, a Simmetry C18 (75 mm × 4.6 mm, 3.5 m), and finally an XTerra RP18 (150 mm × 4.6 
mm, 3.5 m) column, which provided the best separation efficiency.  For the mobile phase, 
different acetonitrile/phosphate buffer ratios and different phosphate buffer concentrations were 
tested.  The mobile phase that gave optimal separation from plasma endogenous peaks was a 70:30 
mixture of acetonitrile and phosphate buffer (v/v).  The optimum pH of the mobile phase buffer 
was determined by changing pH every 0.5 from pH 2 to pH 7.  Finally, pH 6.0 phosphate buffer 
(52.5 mM) for the mobile phase appeared to be optimal to separate SMV.  Isocratic elution was 
preferred, as gradient elution requires control by a gradient HPLC pump system, re-equilibration 
time, perfect solvent mixing, etc.  Column temperature, flow rate, and detection wavelength (i.e., 
225 nm) were all optimized to give the final instrumentation conditions described in Section 2.2.  
The autosampler was thermostated at 20°C, as sample precipitation was observed at lower 
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temperatures.  The stability of SMV under these conditions was investigated (see Section 3.3).  
Representative chromatograms of a control human plasma sample and spiked samples at the 
LLOQ and ULOQ level are shown in Fig. 1. 
 
3.2  Method validation: linearity, recovery, sensitivity, accuracy and precision, selectivity and 
specificity 
A 9-point calibration standard curve of SMV in plasma, ranging from 0.05 to 20 g/ml, was 
prepared in triplicate in four independent runs.  The calibration curves were linear over the tested 
concentration range, with correlation coefficients of 0.997 - 0.999. 
The mean recovery obtained for SMV during the extraction from plasma ranged from 85.9 
to 90.3% in the tested concentration range (0.05-20 g/ml), with the CV ranging from 1.3 to 5.7%. 
These results indicate that the extraction method developed here achieves a high degree of 
efficiency and reproducibility.  
The LLOQ, defined as the lowest concentration in the standard curve that back-calculates 
with good accuracy and precision (bias from -8 to 6%, CV = 8.3%, n = 20; see Table 1), was 
0.050 g/ml.  A typical chromatogram of an LLOQ sample is shown in Fig. 1B.  This LLOQ is 
well below the Ctrough values observed in patients (0.96 g/ml) [10] and thus provides sufficient 
sensitivity for routine analysis of human plasma samples in the clinical setting.  The LOD, defined 
as the concentration giving a signal-to-noise ratio of 3, was 0.02 g/ml. 
The analytical accuracy and precision were evaluated by assaying LLOQ, ULOQ and QC 
samples in five replicates on each of four different days.  The accuracy (expressed as % bias) and 
precision (expressed as % CV) data are summarized in Table 1.  The intra-day and inter-day 
deviations (% bias) from the nominal concentrations were always 8.0% and 6.0%, respectively.  
The CVs for intra-day and inter-day data ranged from 1.4 to 7.2% and from 1.0 to 8.3%, 
respectively.  Thus, both precision and accuracy were <15%, according to guidelines [9]. 
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Furthermore, these values are similar to the values previously reported for the LC-MS/MS method 
measuring SMV concentration in plasma [8].  These results indicate that the method we developed 
achieves a high degree of reproducibility and accuracy. 
Specificity based on endogenous interfering peaks was evaluated in ten different lots of 
commercial control human plasma.  No significant interfering peaks from human plasma were 
found at the retention time of SMV (see Fig. 1A).  The anti-HCV drugs ribavirin, interferon, α, 
daclatasvir, sofosbuvir, and telaprevir did not interfere with the analytical method.  Other drugs 
which were tested included: abacavir, acyclovir, ampicillin, amprenavir, atazanavir, carbenicillin, 
chloramphenicol, daptomycin, didanosine, efavirenz, erythromycin, fluconazole, foscarnet, 
ganciclovir, gentamicin, imipenem, indinavir, kanamycin, lamivudine, linezolid, lopinavir, 
nevirapine, posaconazole, rifampicin, ritonavir, saquinavir, stavudine, streptomycin, teicoplanin, 
telaprevir, tenofovir, tetracycline, vancomycin, voriconazole, zalcitabine, and zidovudine.  None of 
these drugs was found to interfere with the assay.  The absence of analytic interference in patient 
plasma samples was also confirmed by the use of the peak purity testing system and the library 
matching of the Empower software. 
 
3.3  Stability data 
Good stability of SMV in human plasma under some conditions (i.e., 72 h at room temperature, 
1184 days at –20°C, 64 days at -70°C, and after 6 freeze-thaw cycles) has been previously shown 
[8].  However, to the best of our knowledge, no detailed investigation has been previously 
conducted on SMV stability during the thermization procedure (56-60°C for 30-60 min) that is 
recommended to heat-inactivate HCV and/or HIV particles in biological samples for safety issues 
[11, 12].  Our paper reports the first detailed study on SMV stability upon such a heat treatment.  
The slope of the calibration curves of SMV determined with samples subjected to the thermization 
procedure (60°C for 60 min) was similar (mean variation of -6.1  0.3%) to that of the calibration 
curves obtained with non-heated samples.  In addition, Table 2 shows the back-calculated values 
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of both thermized and non-thermized samples using calibration curves established with samples 
subjected or not to the same treatment.  Considering the experimental variability (Table 1), these 
results indicated that such a procedure does not affect SMV concentrations within the considered 
concentration range. 
We also investigated the SMV stability in human plasma under conditions that clinical 
samples commonly experience.  Moreover, we tested the stability of SMV both in dried and in 
reconstituted extracts.  Our results (Table 3) confirmed the good stability of SMV in plasma 
previously reported [11] after repeated freeze/thaw cycles and under short-term storage (3 days) at 
room temperature and long-term storage (3 months) at -80°C.  In addition, SMV was stable both in 
dried extracts kept at -20°C for 5 days and in extracts reconstituted in mobile phase and kept at 
20°C for 4 days (Table 3).   
 
3.4  Analysis of patient samples 
This method has been applied to measure SMV plasma concentrations in samples received by our 
diagnostic Unit from HCV-infected patients and has proved to be robust and sensitive enough for 
routine therapeutic drug monitoring of SMV plasmatic levels.  Fig. 2 shows two representative 
chromatograms of plasma samples from HCV-positive patients receiving SMV.  In these samples, 
observed SMV plasma concentrations were 3.56 µg/ml and 2.59 µg/ml, respectively, which are 
within the concentration range reported by others [10].   
 
4.  Conclusions 
A simple HPLC assay with UV detection for the measurement of SMV concentrations in human 
plasma was established and validated according to the FDA recommendations [9], and was shown 
to be specific, sensitive, and accurate over a concentration range of 0.05-20 g/ml.  Analysis of the 
stability of SMV under various conditions showed that the drug concentration remains stable in 
plasma stored at room temperature for 3 days or at -80°C for up to 3 months as well as in samples 
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undergoing three freeze-thaw cycles and thermal virus inactivation for 60 min at 60°C.  The drug 
is also stable in processed samples, both in dried extracts kept at –20°C for 5 days and in 
reconstituted samples for at least 4 days at 20°C.  The applicability of the method and the 
appropriateness of the validated concentrations ranges have been demonstrated in the analysis of 
plasma samples of HCV-infected subjects.  This simple HPLC method can be conveniently used 
for routine therapeutic drug monitoring of SMV in conventional hospital laboratories wherein LC–
MS/MS is not available. 
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Figure Legends 
 
Fig. 1.  Representative chromatograms obtained after extraction of (A) spiked plasma sample 
containing SMV 20 g/ml (ULOQ), (B) spiked plasma sample containing SMV 0.05 g/ml 
(LLOQ), and (C) blank plasma sample. 
 
Fig. 2.  Chromatograms of plasma samples from HCV-infected patients treated with SMV in 
combination with (A) sofosbuvir and ribavirin; or (B) sofosbuvir.  The measured concentration of 
SMV was 3.56 g/ml in sample (A) and 2.59 g/ml in sample (B). 
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Table 1 
Intra-day and inter-day accuracy and precision results. 
_________________________________________________________________________________________________________ 
Nominal concentration 
(g/ml) 
Intra-day (n = 5) Inter-day (n = 4) 
 
                                                                                                                 ______________________________________________________________________________________________         _________________________________________________________________________________________________ 
 
 Mean measured 
concentration  
(g/ml) 
Accuracya 
(% bias) 
Precision 
(% CV) 
Mean measured 
concentration  
(g/ml) 
Accuracy 
(% bias) 
Precision 
(% CV) 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
      0.05 (LLOQ) 0.046 -8.0 7.2 0.053 6.0 8.3 
      0.2 (low QC) 0.191 -4.5 3.9 0.211 5.5 2.2 
      1.0 (medium QC) 1.012 1.2 2.1 0.967 -3.3 3.1 
      5.0 (high QC) 4.989 -0.2 6.1 5.202 4.0 1.0 
      20.0 (ULOQ) 19.397 -3.0 1.4 20.730 3.7 3.2 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
aAccuracy = [(measured concentration – nominal concentration)/nominal concentration] x 100 
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Table 2 
Back-calculated values of both thermized (T) and non-thermized (NT) plasma samples spiked with SMV using calibration curves established with samples 
subjected or not to heat treatment (60°C for 60 min) 
 
_________________________________________________________________________________________________________________ 
 
Nominal concentration 
(g/ml) 
T vs T 
(g/ml) 
Accuracy 
(%) 
T vs NT 
(g/ml) 
Accuracy 
(%) 
NT vs T 
(g/ml) 
Accuracy 
(%) 
_________________________________________________________________________________________________________________ 
 
0.05 (LLOQ) 0.053 6.0 0.046 -8.0 0.047 -6.0 
0.2 (low QC) 0.196 -2.0 0.213 6.5 0.193 -3.5 
1.0 (medium QC) 1.039 3.9 0.976 -2.4 1.055 5.5 
5.0 (high QC) 4.988 -0.2 4.877 -2.5 5.132 2.6 
20.0 (ULOQ) 20.765 3.8 19.886 -0.6 20.893 4.5 
_________________________________________________________________________________________________________________ 
 
T vs. T: mean concentration of thermized LLOQ, QC, and ULOQ samples back-calculated with the calibration curves established with thermized 
samples; T vs. NT: mean concentration of thermized LLOQ, QC, and ULOQ samples back-calculated with the calibration curves established with 
non-thermized samples; NT vs. T: mean concentration of non-thermized LLOQ, QC, and ULOQ samples back-calculated with the calibration 
curves established with thermized samples. 
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Table 3 
Stability of SMV in plasma samples and in dried or reconstituted extracts under different 
treatment/storage conditions. 
 
                                                                                                          Nominal concentration (g/ml) 
 0.05 0.2 1.0 5.0 20.0 
(A) In plasma subjected to three freeze/thaw cycles      
Mean measured conc. at t=0 (g/ml) 0.049 0.193 1.111 4.865 19.665 
Mean recovered conc. (g/ml) 0.053 0.214 1.053 4.999 20.002 
Deviation (%) 8.2 10.9 -5.22 2.8 1.7 
CV (%) 7.5 5.9 3.3 0.3 1.2 
(B) In plasma stored at room temperature for 72 h      
Mean measured conc. at t=0 (g/ml) 0.051 0.202 0.976 5.133 20.743 
Mean recovered conc. (g/ml) 0.046 0.218 0.988 5.288 19.968 
Deviation (%) -9.8 7.9 1.2 3.0 -3.7 
CV (%) 7.1 6.4 0.9 1.6 1.9 
(C) In plasma stored at – 80°C for three months 
 
     
Mean measured conc. at t=0 (g/ml) 0.049 0.189 1.122 5.088 20.421 
Mean recovered conc. (g/ml) 0.045 0.198 1.133 4.966 20.988 
Deviation (%) -8.2 4.8 1.0 - 2.4 2.8 
CV (%) 6.5 3.2 1.9 2.8 3.1 
(D) In dried extracts stored at – 20°C for 120 h      
Mean measured conc. at t=0 (g/ml) 0.058 0.218 0.954 5.265 20.955 
Mean recovered conc. (g/ml) 0.054 0.205 1.003 5.304 19.742 
Deviation (%) -6.9 -6.0 5.1 0.7 -5.8 
CV (%) 5.7 0.1 3.8 4.0 2.9 
(E) In reconstituted extracts stored at 20°C for 96 h      
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Mean measured conc. at t=0 (g/ml) 0.049 0.209 0.977 4.966 19.876 
Mean recovered conc. (g/ml) 0.053 0.198 1.044 5.087 20.566 
Deviation (%) 8.2 -5.3 6.9 2.4 3.5 
CV (%) 6.7 7.8 2.0 3.8 1.6 
 
